癌症的进化、适应性免疫和免疫治疗

Autumn J. Smith
{"title":"癌症的进化、适应性免疫和免疫治疗","authors":"Autumn J. Smith","doi":"10.30683/1927-7229.2019.08.04","DOIUrl":null,"url":null,"abstract":": The first clinical trials to investigate the efficacy of immunotherapy in cancer were problematic because of issues related to product availability, cost, and purity. Moreover, these factors could have contributed to the modest efficacy of these agents. The ability to clone specific genes coupled with the development of recombinant DNA technology removed some major barriers such that only 20 years later, approval of the first engineered monoclonal antibody (mAb) for clinical use occurred with practice-changing implications. Subsequent to rituximab, more than 30 additional mAbs have indications for a number of hematologic malignancies and solid tumors. Indeed, the application of adaptive immunity is now an integral component of therapy for many cancers. This paper delves into the complex science of immunology by investigating how the term evolution is applicable to tumorigenesis, the adaptive immune response, and cancer therapy.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"51 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evolution of Cancer, Adaptive Immunity, and Immunotherapy\",\"authors\":\"Autumn J. Smith\",\"doi\":\"10.30683/1927-7229.2019.08.04\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": The first clinical trials to investigate the efficacy of immunotherapy in cancer were problematic because of issues related to product availability, cost, and purity. Moreover, these factors could have contributed to the modest efficacy of these agents. The ability to clone specific genes coupled with the development of recombinant DNA technology removed some major barriers such that only 20 years later, approval of the first engineered monoclonal antibody (mAb) for clinical use occurred with practice-changing implications. Subsequent to rituximab, more than 30 additional mAbs have indications for a number of hematologic malignancies and solid tumors. Indeed, the application of adaptive immunity is now an integral component of therapy for many cancers. This paper delves into the complex science of immunology by investigating how the term evolution is applicable to tumorigenesis, the adaptive immune response, and cancer therapy.\",\"PeriodicalId\":14957,\"journal\":{\"name\":\"Journal of Analytical Oncology\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Analytical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30683/1927-7229.2019.08.04\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Analytical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30683/1927-7229.2019.08.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

由于产品可得性、成本和纯度等问题,研究免疫疗法对癌症疗效的首批临床试验存在问题。此外,这些因素可能导致这些药物的疗效不高。克隆特定基因的能力加上重组DNA技术的发展消除了一些主要障碍,仅在20年后,首个用于临床的工程单克隆抗体(mAb)就获得批准,并改变了实践意义。继利妥昔单抗之后,又有30多种单克隆抗体适用于多种血液恶性肿瘤和实体肿瘤。事实上,适应性免疫的应用现在是许多癌症治疗的一个组成部分。本文通过研究进化这一术语如何适用于肿瘤发生、适应性免疫反应和癌症治疗,深入研究了免疫学的复杂科学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evolution of Cancer, Adaptive Immunity, and Immunotherapy
: The first clinical trials to investigate the efficacy of immunotherapy in cancer were problematic because of issues related to product availability, cost, and purity. Moreover, these factors could have contributed to the modest efficacy of these agents. The ability to clone specific genes coupled with the development of recombinant DNA technology removed some major barriers such that only 20 years later, approval of the first engineered monoclonal antibody (mAb) for clinical use occurred with practice-changing implications. Subsequent to rituximab, more than 30 additional mAbs have indications for a number of hematologic malignancies and solid tumors. Indeed, the application of adaptive immunity is now an integral component of therapy for many cancers. This paper delves into the complex science of immunology by investigating how the term evolution is applicable to tumorigenesis, the adaptive immune response, and cancer therapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信